| Dexamethasone in hospitalized patients with Covid-19—preliminary report TRC Group The New England journal of medicine, 2020 | 5966* | 2020 |
| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 3433 | 2021 |
| Estimated transmissibility and impact of SARS-CoV-2 lineage B. 1.1. 7 in England NG Davies, S Abbott, RC Barnard, CI Jarvis, AJ Kucharski, JD Munday, ... Science 372 (6538), eabg3055, 2021 | 1655 | 2021 |
| SARS-CoV-2 variants, spike mutations and immune escape WT Harvey, AM Carabelli, B Jackson, RK Gupta, EC Thomson, ... Nature Reviews Microbiology 19 (7), 409-424, 2021 | 1234 | 2021 |
| Effect of hydroxychloroquine in hospitalized patients with Covid-19 RECOVERY Collaborative Group New England Journal of Medicine 383 (21), 2030-2040, 2020 | 871 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 834 | 2021 |
| Tuberculous meningitis: a uniform case definition for use in clinical research S Marais, G Thwaites, JF Schoeman, ME Török, UK Misra, K Prasad, ... The Lancet infectious diseases 10 (11), 803-812, 2010 | 788 | 2010 |
| Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity E Volz, V Hill, JT McCrone, A Price, D Jorgensen, Á O’Toole, J Southgate, ... Cell 184 (1), 64-75. e11, 2021 | 759 | 2021 |
| The Influence of Host and Bacterial Genotype on the Development of Disseminated Disease with Mycobacterium tuberculosis M Caws, G Thwaites, S Dunstan, TR Hawn, N Thi Ngoc Lan, NTT Thuong, ... PLoS pathogens 4 (3), e1000034, 2008 | 604 | 2008 |
| Whole-genome sequencing for analysis of an outbreak of meticillin-resistant Staphylococcus aureus: a descriptive study SR Harris, EJP Cartwright, ME Török, MTG Holden, NM Brown, ... The Lancet infectious diseases 13 (2), 130-136, 2013 | 602 | 2013 |
| Assessing transmissibility of SARS-CoV-2 lineage B. 1.1. 7 in England E Volz, S Mishra, M Chand, JC Barrett, R Johnson, L Geidelberg, ... Nature 593 (7858), 266-269, 2021 | 601 | 2021 |
| SARS-CoV-2 evolution during treatment of chronic infection SA Kemp, DA Collier, RP Datir, IATM Ferreira, S Gayed, A Jahun, ... Nature 592 (7853), 277-282, 2021 | 549 | 2021 |
| Sensitivity of SARS-CoV-2 B. 1.1. 7 to mRNA vaccine-elicited antibodies DA Collier, A De Marco, IATM Ferreira, B Meng, RP Datir, AC Walls, ... Nature 593 (7857), 136-141, 2021 | 491 | 2021 |
| Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission L Rivett, S Sridhar, D Sparkes, M Routledge, NK Jones, S Forrest, ... elife 9, e58728, 2020 | 487 | 2020 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... The Lancet 397 (10282), 1351-1362, 2021 | 476 | 2021 |
| Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity EC Thomson, LE Rosen, JG Shepherd, R Spreafico, A da Silva Filipe, ... Cell 184 (5), 1171-1187. e20, 2021 | 398 | 2021 |
| Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial PW Horby, M Mafham, JL Bell, L Linsell, N Staplin, J Emberson, ... The Lancet 396 (10259), 1345-1352, 2020 | 374 | 2020 |
| Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)–associated tuberculous meningitis ME Török, NTB Yen, TTH Chau, NTH Mai, NH Phu, PP Mai, NT Dung, ... Clinical infectious diseases 52 (11), 1374-1383, 2011 | 351 | 2011 |
| Taking the right measures to control COVID-19 Y Xiao, ME Torok The Lancet Infectious Diseases 20 (5), 523-524, 2020 | 322 | 2020 |
| Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort study KA Twohig, T Nyberg, A Zaidi, S Thelwall, MA Sinnathamby, S Aliabadi, ... The Lancet Infectious Diseases 22 (1), 35-42, 2022 | 321 | 2022 |
Sharon J PeacockUniversity of CambridgeVerified email at medschl.cam.ac.uk
